NKGen Biotech dosed first patient with SNK01 in the P-I/IIa study investigating safety, efficacy, MTD and/or RP2D for the treatment of moderate Alzheimer’s disease (AD)
In P-I dose-escalation safety study, SNK01 exhibited improved neuroinflammation and cognitive function in Alzheimer’s Disease patients
SNK01 is an innovative, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug candidate that is also under development for the treatment of wide range of cancers
Ref: NKGen Biotech | Image: NKGen Biotech
Related News:- Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
